European Primary Care Cardiovascular Society
A consensus document by a group of representatives from primary and secondary care has been published on the management of diabetes for patients at risk or with confirmed COVID-19.
Cumulative incidences of diagnosed and symptomatic VTE are increased in COVID-19 patients hospitalized in a Dutch hospital, with higher risk in those admitted to the ICU as compared to the general ward.
Treatment with liraglutide plus lifestyle therapy led to a greater reduction in BMI standard-deviation score than placebo plus lifestyle therapy in adolescents with obesity.
This observational study in 184 patients with COVID-19 pneumonia admitted to the ICU in the Netherlands showed a cumulative incidence of venous thromboembolism and arterial thrombotic complications of 31%.
This presentation is part of a webinar on COVID-19, ACE2 and RAAS inhibition and focuses on the scientific data that is available on the ACE2 receptor and RAAS inhibitors.
As part of a webinar on COVID-19, ACE2 and RAASi, prof. Epstein presents what the clinical implications are of discontinuation of RAASi in COVID-19 patients and strongly recommends to continue use of these medications.
As many questions arise on COVID-19, ACE2 and RAAS inhibition, 3 experts discuss some of the issues on this topic as part of a webinar.
This commentary article describes the function of ACE2, the receptor responsible for SARS-CoV-2 entry, and describes why continued use of RAS blockers during the COVID-19 pandemic is recommended.
The FDA approved dapagliflozin for treatment of heart failure patients with reduced ejection fraction to reduce CV death and hospitalization for HF.
In a letter to the editor, Baldi and colleagues describe a study on the incidence of out-of-hospital cardiac arrest in 4 provinces in Lombardy, Italy, during the initial outbreak of COVID-19.
In elderly patients, who have higher risk of bleeding and thrombotic events, treatment with clopidogrel reduced bleeding, while net clinical benefit was not increased compared to stronger P2Y12 inhibitors.
Total (first and subsequent) vascular events among patients with recent stroke or transient ischemic attack were reduced, as shown in a post-hoc analysis of the SPARCL trial.
